These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36206607)

  • 41. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.
    Karmochkine M; Si Mohamed A; Piketty C; Ginsburg C; Raguin G; Schneider-Fauveau V; Gutmann L; Kazatchkine MD; Belec L
    Antiviral Res; 2000 Sep; 47(3):179-88. PubMed ID: 10974370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
    Paredes R; Puig T; Arnó A; Negredo E; Balagué M; Bonjoch A; Jou A; Tuldrà A; Tural C; Sirera G; Veny A; Romeu J; Ruiz L; Clotet B
    J Acquir Immune Defic Syndr; 1999 Oct; 22(2):132-8. PubMed ID: 10843526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
    Katzenstein TL; Kirk O; Pedersen C; Lundgren JD; Nielsen H; Obel N; Nielsen C; Mathiesen LR; Gerstoft J
    J Infect Dis; 2000 Sep; 182(3):744-50. PubMed ID: 10950767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.
    Goldfarb NE; Ohanessian M; Biswas S; McGee TD; Mahon BP; Ostrov DA; Garcia J; Tang Y; McKenna R; Roitberg A; Dunn BM
    Biochemistry; 2015 Jan; 54(2):422-33. PubMed ID: 25513833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
    Robbins BL; Capparelli EV; Chadwick EG; Yogev R; Serchuck L; Worrell C; Smith ME; Alvero C; Fenton T; Heckman B; Pelton SI; Aldrovandi G; Borkowsky W; Rodman J; Havens PL;
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3276-83. PubMed ID: 18625762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.
    Mouroux M; Yvon-Groussin A; Peytavin G; Delaugerre C; Legrand M; Bossi P; Do B; Trylesinski A; Diquet B; Dohin E; Delfraissy JF; Katlama C; Calvez V
    J Clin Microbiol; 2000 Jul; 38(7):2726-30. PubMed ID: 10878071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
    Marin-Niebla A; Lopez-Cortes LF; Ruiz-Valderas R; Viciana P; Mata R; Gutierrez A; Pascual R; Rodriguez M
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2035-42. PubMed ID: 17371813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.
    Pettoello-Mantovani M; Kollmann TR; Raker C; Kim A; Yurasov S; Tudor R; Wiltshire H; Goldstein H
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1880-7. PubMed ID: 9303378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effectiveness of combined saquinavir and ketoconazole treatment in reducing HIV viral load.
    Jordan WC
    J Natl Med Assoc; 1998 Oct; 90(10):622-4. PubMed ID: 9803727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dysregulation of Autophagy Contributes to Anal Carcinogenesis.
    Carchman EH; Matkowskyj KA; Meske L; Lambert PF
    PLoS One; 2016; 11(10):e0164273. PubMed ID: 27706233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
    AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
    Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
    Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group.
    Nieuwkerk PT; Gisolf EH; Colebunders R; Wu AW; Danner SA; Sprangers MA
    AIDS; 2000 Jan; 14(2):181-7. PubMed ID: 10708289
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors.
    Gunder LC; Moyer TH; Johnson HR; Auyeung AS; Leverson GE; Zhang W; Matkowskyj KA; Carchman EH
    J Surg Res; 2023 Feb; 282():137-146. PubMed ID: 36274448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.